EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

Mise à jour : Il y a 4 ans
Référence : NCT00470678

Femme et Homme

Extrait

This study will evaluate efficacy and safety for monthly ranibizumab 0.5 mg intravitreal injections in Asian patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.


Critère d'inclusion

  • Choroidal Neovascularization ,Age-related macular degeneration

Liens